Eletriptan
Selective Serotonin (5ht1) Agonists
Sold as RELPAX
- Drug class
- Selective Serotonin (5ht1) Agonists
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 43
Overview
Eletriptan is an active pharmaceutical ingredient in the Selective Serotonin (5ht1) Agonists group (N02CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 25 | May 22, 2026 |
| CA Canada | Health Canada | 16 | May 7, 2026 |
| US United States | FDA | 2 | January 22, 2025 |
GBUnited Kingdom· MHRA
25 products
Uses
Eletriptan is indicated in adults for the acute treatment of the headache phase of migraine attacks, with or without aura.
How to take
CACanada· Health Canada
16 products
Uses
30 RELPAX (eletriptan hydrobromide) – Product Monograph Page 3 of 32 PrRELPAX® (eletriptan hydrobromide tablets) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength All Nonmedicinal Ingredients Oral Tablets 20 mg, 40 mg Croscarmellose sodium, FD & C Yellow No 6 aluminum lake, hypromellose, lactose monohydrate, microcrystalline cellulose, magnesium stearate, titanium dioxide and triacetin.
INDICATIONS AND CLINICAL USE Adults RELPAX (eletriptan hydrobromide) is indicated for the acute treatment of migraine with or without aura in adults. RELPAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see CONTRAINDICATIONS).
Safety and effectiveness of RELPAX tablets have not been established for cluster headache, which is present in an older, predominantly male population. Pediatrics (< 18 years of age) The safety and efficacy of RELPAX in children has not been established and its use in this age group is not recommended.
USUnited States· FDA
2 products
Uses
Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks.
Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache.
How to take
Drug interactions
Known interactions involving Eletriptan. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 249. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL461300015 · revised January 16, 2026
- [2]Health Canada (DPD) · 02256290 · revised March 22, 2025
- [3]FDA DailyMed · 077134d1-427d-62… · revised January 22, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.